335(top 100%)
PR articles
55.0K(top 0.1%)
PR citations
114(top 100%)
PR h-index
130(top 100%)
h-index
376
documents
70.6K
doc citations
4.0K
citing journals
100
times ranked

Publications

335 PR articles • 57,382 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | PR Citations
#ArticleIFPR CitationsLinks
1Pre-exposure antibody prophylaxis protects macaques from severe influenza
Science, 2025, 387, 534-541
37.010Citations (PDF)
2Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice
Science Translational Medicine, 2024, 16,
13.437Citations (PDF)
3Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
PLoS Medicine, 2024, 21, e1004329
8.19Citations (PDF)
4A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo
Science Translational Medicine, 2024, 16,
13.42Citations (PDF)
5A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
Science Translational Medicine, 2022, 14,
13.4125Citations (PDF)
6Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
Cell, 2022, 185, 113-130.e15
34.479Citations (PDF)
7Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Journal of Infectious Diseases, 2022, 226, 510-520
3.932Citations (PDF)
8Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
Nature Medicine, 2022, 28, 383-391
40.4141Citations (PDF)
9mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Cell, 2022, 185, 1556-1571.e18
34.4218Citations (PDF)
10Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Science, 2022, 376,
37.0161Citations (PDF)
11Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Advanced Science, 2022, 9,
12.79Citations (PDF)
12Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2
Journal of Biological Chemistry, 2022, 298, 101819
2.314Citations (PDF)
13Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Nature Medicine, 2022, 28, 1022-1030
40.477Citations (PDF)
14LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Cell Reports, 2022, 39, 110812
6.4420Citations (PDF)
15Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
Lancet Infectious Diseases, The, 2022, 22, 1210-1220
15.734Citations (PDF)
16Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Nature Medicine, 2022, 28, 1288-1296
40.4117Citations (PDF)
17Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
PLoS ONE, 2022, 17, e0268767
2.426Citations (PDF)
18Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
EClinicalMedicine, 2022, 48, 101477
8.536Citations (PDF)
19Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine
Science Translational Medicine, 2022, 14,
13.412Citations (PDF)
20Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4
PLoS Pathogens, 2022, 18, e1010574
4.514Citations (PDF)
21Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
Structure, 2022, 30, 1233-1244.e7
3.934Citations (PDF)
22Broadly neutralizing antibodies target the coronavirus fusion peptide
Science, 2022, 377, 728-735
37.0244Citations (PDF)
23Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition
Immunity, 2022, 55, 2135-2148.e6
23.323Citations (PDF)
24Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth
Science, 2021, 371,
37.085Citations (PDF)
25Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach
Clinical Pharmacology and Therapeutics, 2021, 109, 184-192
4.88Citations (PDF)
26Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
Vaccines, 2021, 9, 73
3.132Citations (PDF)
27Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine, 2021, 384, 403-416
44.09,943Citations (PDF)
28Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
EBioMedicine, 2021, 64, 103203
10.025Citations (PDF)
29Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates
Science Translational Medicine, 2021, 13,
13.471Citations (PDF)
30Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
New England Journal of Medicine, 2021, 384, 1003-1014
44.0470Citations (PDF)
31Quadrivalent influenza nanoparticle vaccines induce broad protection
Nature, 2021, 592, 623-628
39.5293Citations (PDF)
32Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Nature, 2021, 593, 130-135
39.52,223Citations (PDF)
33The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Science Translational Medicine, 2021, 13,
13.4421Citations (PDF)
34Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses
Immunity, 2021, 54, 769-780.e6
23.360Citations (PDF)
35Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1–Exposed Newborn Infants
Journal of Infectious Diseases, 2021, 224, 1916-1924
3.947Citations (PDF)
36Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Science, 2021, 373,
37.0199Citations (PDF)
37Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
PLoS Pathogens, 2021, 17, e1009738
4.512Citations (PDF)
38In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Cell, 2021, 184, 4203-4219.e32
34.4307Citations (PDF)
39Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Immunity, 2021, 54, 1636-1651
23.3238Citations (PDF)
40Blocking α <sub>4</sub> β <sub>7</sub> integrin delays viral rebound in SHIV <sub>SF162P3</sub> -infected macaques treated with anti-HIV broadly neutralizing antibodies
Science Translational Medicine, 2021, 13,
13.414Citations (PDF)
41A Monoclonal Antibody for Malaria Prevention
New England Journal of Medicine, 2021, 385, 803-814
44.0148Citations (PDF)
42Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
Science Translational Medicine, 2021, 13,
13.4116Citations (PDF)
43Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Science, 2021, 373, 1372-1377
37.0543Citations (PDF)
44Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
Science, 2021, 373,
37.0301Citations (PDF)
45Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses
Proceedings of the National Academy of Sciences of the United States of America, 2021, 118,
7.826Citations (PDF)
46Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization
PLoS Pathogens, 2021, 17, e1009543
4.57Citations (PDF)
47Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging
Journal of Clinical Investigation, 2021, 131,
9.06Citations (PDF)
48Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
New England Journal of Medicine, 2021, 385, 1774-1785
44.0539Citations (PDF)
49SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity
Journal of Biological Chemistry, 2021, 297, 101127
2.316Citations (PDF)
50Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Lancet Respiratory Medicine,the, 2021, 9, 1111-1120
24.157Citations (PDF)
51Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Science, 2021, 374, 1343-1353
37.095Citations (PDF)
52A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
Nature Medicine, 2021, 27, 2234-2245
40.4154Citations (PDF)
53Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine
Frontiers in Immunology, 2021, 12,
5.157Citations (PDF)
54Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants
Journal of Infectious Diseases, 2020, 222, 628-636
3.955Citations (PDF)
55Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses
Journal of Experimental Medicine, 2020, 217,
8.027Citations (PDF)
56Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
Nature Communications, 2020, 11,
13.953Citations (PDF)
57SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Nature, 2020, 586, 567-571
39.51,481Citations (PDF)
58Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes
Cell Reports, 2020, 33, 108322
6.471Citations (PDF)
59Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18754-18763
7.879Citations (PDF)
60An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
New England Journal of Medicine, 2020, 383, 1920-1931
44.03,090Citations (PDF)
61Development of a potent Zika virus vaccine using self-amplifying messenger RNA
Science Advances, 2020, 6,
11.274Citations (PDF)
62Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
New England Journal of Medicine, 2020, 383, 1544-1555
44.01,058Citations (PDF)
63Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature
Cell Reports, 2020, 32, 107981
6.425Citations (PDF)
64Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide
Vaccines, 2020, 8, 765
3.119Citations (PDF)
65Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development
Frontiers in Immunology, 2020, 11,
5.176Citations (PDF)
66Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality
Science Translational Medicine, 2020, 12,
13.444Citations (PDF)
67VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage
Cell Host and Microbe, 2020, 27, 531-543.e6
15.529Citations (PDF)
68Immune checkpoint modulation enhances HIV-1 antibody induction
Nature Communications, 2020, 11,
13.934Citations (PDF)
69Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials
PLoS Computational Biology, 2020, 16, e1007626
3.228Citations (PDF)
70HIV-1 gp120–CD4-Induced Antibody Complex Elicits CD4 Binding Site–Specific Antibody Response in Mice
Journal of Immunology, 2020, 204, 1543-1561
0.68Citations (PDF)
71Next-generation influenza vaccines: opportunities and challenges
Nature Reviews Drug Discovery, 2020, 19, 239-252
75.6304Citations (PDF)
72Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition
Cell Reports, 2020, 31, 107488
6.474Citations (PDF)
73Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes
JAMA - Journal of the American Medical Association, 2020, 323, 1369
17.299Citations (PDF)
74A proof of concept for structure-based vaccine design targeting RSV in humans
Science, 2019, 365, 505-509
37.0307Citations (PDF)
75Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
PLoS Pathogens, 2019, 15, e1007776
4.518Citations (PDF)
76Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization
Cell, 2019, 178, 567-584.e19
34.4150Citations (PDF)
77Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations
Nature Communications, 2019, 10,
13.940Citations (PDF)
78Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
BMJ Open, 2019, 9, e030283
2.016Citations (PDF)
79Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates
Scientific Reports, 2019, 9,
3.544Citations (PDF)
80A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge
Cell Host and Microbe, 2019, 26, 336-346.e3
15.5123Citations (PDF)
81Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
Lancet HIV,the, 2019, 6, e667-e679
8.1102Citations (PDF)
82Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
PLoS Pathogens, 2019, 15, e1008026
4.574Citations (PDF)
83Comparison of adjuvants to optimize influenza neutralizing antibody responses
Vaccine, 2019, 37, 6208-6220
3.227Citations (PDF)
84Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
Lancet, The, 2019, 393, 889-898
52.0120Citations (PDF)
85Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Immunity, 2019, 50, 1513-1529.e9
23.398Citations (PDF)
86A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates
Science Translational Medicine, 2019, 11,
13.464Citations (PDF)
87Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting
PLoS ONE, 2019, 14, e0215163
2.454Citations (PDF)
88Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Lancet HIV,the, 2019, 6, e297-e306
8.194Citations (PDF)
89Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages
MBio, 2019, 10,
4.5133Citations (PDF)
90Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual
Immunity, 2019, 50, 677-691.e13
23.3111Citations (PDF)
91Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
Nature Immunology, 2019, 20, 362-372
24.4302Citations (PDF)
92Improvement of antibody functionality by structure-guided paratope engraftment
Nature Communications, 2019, 10,
13.937Citations (PDF)
93Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability
Immunity, 2019, 51, 915-929.e7
23.3138Citations (PDF)
94Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry
Nature Communications, 2019, 10,
13.954Citations (PDF)
95Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition
Structure, 2019, 27, 196-206.e6
3.988Citations (PDF)
96HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Cell Host and Microbe, 2019, 25, 59-72.e8
15.5171Citations (PDF)
97Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
Journal of Clinical Investigation, 2019, 129, 4838-4849
9.0115Citations (PDF)
98Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B
Pathogens and Immunity, 2019, 4, 294
1.630Citations (PDF)
99Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape
Journal of Virology, 2018, 92,
3.7168Citations (PDF)
100Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
Nature Communications, 2018, 9,
13.975Citations (PDF)
101Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens
ACS Infectious Diseases, 2018, 4, 788-796
3.789Citations (PDF)
102Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
Cell Reports, 2018, 22, 1798-1809
6.471Citations (PDF)
103Functional interrogation and mining of natively paired human VH:VL antibody repertoires
Nature Biotechnology, 2018, 36, 152-155
32.5137Citations (PDF)
104Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
Human Vaccines and Immunotherapeutics, 2018, 14, 2116-2127
3.118Citations (PDF)
105Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection
Journal of Infectious Diseases, 2018, 217, 1530-1534
3.97Citations (PDF)
106Is It Possible to Develop a “Universal” Influenza Virus Vaccine?
Cold Spring Harbor Perspectives in Biology, 2018, 10, a029413
7.445Citations (PDF)
107Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Lancet, The, 2018, 391, 552-562
52.0282Citations (PDF)
108Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4
Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12265-12270
7.8102Citations (PDF)
109HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
PLoS Pathogens, 2018, 14, e1007431
4.545Citations (PDF)
110Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
Immunity, 2018, 49, 1162-1174.e8
23.369Citations (PDF)
111Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge
PLoS Pathogens, 2018, 14, e1007395
4.550Citations (PDF)
112HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Immunity, 2018, 48, 855-871
23.3329Citations (PDF)
113Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation
PLoS Pathogens, 2018, 14, e1007024
4.528Citations (PDF)
114Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV
PLoS Pathogens, 2018, 14, e1007159
4.551Citations (PDF)
115Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
Nature Medicine, 2018, 24, 857-867
40.4306Citations (PDF)
116Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
PLoS Medicine, 2018, 15, e1002493
8.1230Citations (PDF)
117Potential of conventional &amp; bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C &amp; D infections
PLoS Pathogens, 2018, 14, e1006860
4.581Citations (PDF)
118Accumulation of follicular CD8+ T cells in pathogenic SIV infection
Journal of Clinical Investigation, 2018, 128, 2089-2103
9.053Citations (PDF)
119Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
PLoS ONE, 2018, 13, e0193773
2.425Citations (PDF)
120Chimpanzee Adenovirus Vector Ebola Vaccine
New England Journal of Medicine, 2017, 376, 928-938
44.0273Citations (PDF)
121Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
Science Translational Medicine, 2017, 9,
13.4159Citations (PDF)
122Use of broadly neutralizing antibodies for <scp>HIV</scp>‐1 prevention
Immunological Reviews, 2017, 275, 296-312
6.6140Citations (PDF)
123The quest for an antibody‐based <scp>HIV</scp> vaccine
Immunological Reviews, 2017, 275, 5-10
6.6104Citations (PDF)
124Antibodyomics: bioinformatics technologies for understanding B‐cell immunity to <scp>HIV</scp>‐1
Immunological Reviews, 2017, 275, 108-128
6.637Citations (PDF)
125Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity
Journal of Virology, 2017, 91,
3.792Citations (PDF)
126Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
Science Immunology, 2017, 2,
14.4148Citations (PDF)
127Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach
Immunity, 2017, 46, 804-817.e7
23.3117Citations (PDF)
128Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation
Cell Reports, 2017, 19, 719-732
6.4185Citations (PDF)
129Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity
Journal of Biological Chemistry, 2017, 292, 10197-10219
2.333Citations (PDF)
130Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys
Journal of Virology, 2017, 91,
3.750Citations (PDF)
131Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
Science Translational Medicine, 2017, 9,
13.4260Citations (PDF)
132Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
Science Translational Medicine, 2017, 9,
13.490Citations (PDF)
133Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
Nature Chemical Biology, 2017, 13, 1115-1122
12.2126Citations (PDF)
134Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Science, 2017, 358, 85-90
37.0254Citations (PDF)
135Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail
Science Translational Medicine, 2017, 9,
13.4123Citations (PDF)
136Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
Science Translational Medicine, 2017, 9,
13.494Citations (PDF)
137Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies
Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8614-8619
7.847Citations (PDF)
138Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys
Journal of Virology, 2017, 91,
3.745Citations (PDF)
139Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
Statistical Communications in Infectious Diseases, 2017, 9,
0.766Citations (PDF)
140Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation
Frontiers in Immunology, 2017, 8,
5.195Citations (PDF)
141Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
PLoS Pathogens, 2017, 13, e1006148
4.561Citations (PDF)
142Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
PLoS Medicine, 2017, 14, e1002435
8.1120Citations (PDF)
143Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations
Nature Communications, 2017, 8,
13.984Citations (PDF)
144Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
PLoS ONE, 2017, 12, e0185959
2.433Citations (PDF)
145Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
PLoS ONE, 2017, 12, e0186854
2.452Citations (PDF)
146Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape
PLoS Pathogens, 2017, 13, e1006074
4.541Citations (PDF)
147SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts
Frontiers in Immunology, 2016, 7,
5.178Citations (PDF)
148Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection
PLoS Computational Biology, 2016, 12, e1004940
3.237Citations (PDF)
149Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
PLoS Pathogens, 2016, 12, e1005520
4.5182Citations (PDF)
150Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
PLoS Pathogens, 2016, 12, e1005537
4.567Citations (PDF)
151Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor
Immunity, 2016, 44, 939-950
23.394Citations (PDF)
152Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
Cell, 2016, 165, 813-826
34.4433Citations (PDF)
153Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design
Journal of Virology, 2016, 90, 5899-5914
3.773Citations (PDF)
154Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
Science, 2016, 352, 828-833
37.0370Citations (PDF)
155Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant
Bioconjugate Chemistry, 2016, 27, 2372-2385
3.848Citations (PDF)
156Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires
Cell, 2016, 166, 1471-1484.e18
34.4240Citations (PDF)
157Rapid development of a DNA vaccine for Zika virus
Science, 2016, 354, 237-240
37.0384Citations (PDF)
158Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding
Journal of Virology, 2016, 90, 10574-10586
3.740Citations (PDF)
159Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies
Structure, 2016, 24, 1346-1357
3.940Citations (PDF)
160Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
Nature Structural and Molecular Biology, 2016, 23, 811-820
8.7157Citations (PDF)
161Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
Cell, 2016, 166, 609-623
34.4340Citations (PDF)
162Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
Immunity, 2016, 45, 1108-1121
23.3385Citations (PDF)
163Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
New England Journal of Medicine, 2016, 375, 2037-2050
44.0459Citations (PDF)
164An HIV-1 Env–Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes
Journal of Immunology, 2016, 197, 3982-3998
0.621Citations (PDF)
165Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
Nature Medicine, 2016, 22, 1456-1464
40.4309Citations (PDF)
166Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques
Nature Medicine, 2016, 22, 362-368
40.4185Citations (PDF)
167High-Resolution Longitudinal Study of HIV-1 Env Vaccine–Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence
Journal of Immunology, 2016, 196, 3729-3743
0.630Citations (PDF)
168Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Science, 2016, 351, 1339-1342
37.0411Citations (PDF)
169Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
Cell, 2016, 165, 449-463
34.4344Citations (PDF)
170Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody
Journal of Virology, 2016, 90, 2740-2755
3.760Citations (PDF)
171Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs
Journal of Virology, 2016, 90, 1321-1332
3.781Citations (PDF)
172New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency
Journal of Virology, 2016, 90, 76-91
3.7238Citations (PDF)
173Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8
PLoS ONE, 2016, 11, e0157409
2.457Citations (PDF)
174A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus
PLoS ONE, 2015, 10, e0128779
2.446Citations (PDF)
175Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env
Journal of Virology, 2015, 89, 5318-5329
3.7144Citations (PDF)
176Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
Cell, 2015, 161, 1280-1292
34.4347Citations (PDF)
177Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Science Translational Medicine, 2015, 7,
13.4441Citations (PDF)
178Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
Lancet, The, 2015, 385, 1545-1554
52.0119Citations (PDF)
179HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies
Journal of Virology, 2015, 89, 4201-4213
3.7146Citations (PDF)
180Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes
Journal of Virology, 2015, 89, 2659-2671
3.7133Citations (PDF)
181Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
PLoS Pathogens, 2015, 11, e1004932
4.5146Citations (PDF)
182Evaluation of candidate vaccine approaches for MERS-CoV
Nature Communications, 2015, 6,
13.9282Citations (PDF)
183Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
Science, 2015, 349,
37.0206Citations (PDF)
184Quality and quantity of T <sub>FH</sub> cells are critical for broad antibody development in SHIV <sub>AD8</sub> infection
Science Translational Medicine, 2015, 7,
13.4129Citations (PDF)
185Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env
Nature Structural and Molecular Biology, 2015, 22, 522-531
8.7375Citations (PDF)
186Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization
Nature Communications, 2015, 6,
13.993Citations (PDF)
187Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization
Journal of Immunology, 2015, 194, 5903-5914
0.624Citations (PDF)
188Antibody responses to envelope glycoproteins in HIV-1 infection
Nature Immunology, 2015, 16, 571-576
24.4385Citations (PDF)
189Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection
Cell, 2015, 161, 470-485
34.4251Citations (PDF)
190Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
Journal of Virology, 2015, 89, 5895-5903
3.7103Citations (PDF)
191Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development
Vaccine, 2015, 33, 7344-7351
3.219Citations (PDF)
192Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Cell, 2015, 162, 1090-1100
34.4364Citations (PDF)
193Activation and lysis of human CD4 cells latently infected with HIV-1
Nature Communications, 2015, 6,
13.995Citations (PDF)
194Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection
Journal of Virology, 2015, 89, 8334-8345
3.7114Citations (PDF)
195Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas
MBio, 2015, 6,
4.531Citations (PDF)
196Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses
Cell Host and Microbe, 2015, 18, 354-362
15.572Citations (PDF)
197Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
Nature Structural and Molecular Biology, 2015, 23, 81-90
8.7185Citations (PDF)
198Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
Science Translational Medicine, 2014, 6,
13.4240Citations (PDF)
199HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization
PLoS Pathogens, 2014, 10, e1004337
4.525Citations (PDF)
200Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6
Journal of Virology, 2014, 88, 2426-2441
3.744Citations (PDF)
201Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
Journal of Immunological Methods, 2014, 409, 131-146
1.5540Citations (PDF)
202Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline
Journal of Immunology, 2014, 192, 1100-1106
0.694Citations (PDF)
203Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Nature, 2014, 509, 55-62
39.5737Citations (PDF)
204Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
Journal of Experimental Medicine, 2014, 211, 2061-2074
8.0330Citations (PDF)
205Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i>
Journal of Virology, 2014, 88, 12669-12682
3.7287Citations (PDF)
206Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Journal of Virology, 2014, 88, 2489-2507
3.7337Citations (PDF)
207Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies
Cell Host and Microbe, 2014, 16, 304-313
15.5151Citations (PDF)
208Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
Cell, 2014, 158, 481-491
34.4291Citations (PDF)
209Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies
Journal of Virology, 2014, 88, 12623-12643
3.780Citations (PDF)
210Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
Lancet, The, 2014, 384, 2046-2052
52.0229Citations (PDF)
211Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization
Journal of Immunology, 2014, 192, 3637-3644
0.660Citations (PDF)
212Structure and immune recognition of trimeric pre-fusion HIV-1 Env
Nature, 2014, 514, 455-461
39.5775Citations (PDF)
213Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies
Journal of Virology, 2014, 88, 14002-14016
3.749Citations (PDF)
214Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Nature Medicine, 2014, 20, 1126-1129
40.4333Citations (PDF)
215Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Aids, 2014, 28, 163-169
2.5372Citations (PDF)
216An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1
Journal of Clinical Investigation, 2014, 124, 1835-1843
9.098Citations (PDF)
217Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies
Immunity, 2013, 39, 245-258
23.3390Citations (PDF)
218Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5 Å Cocrystal Structure of gp120 and M48U1
Structure, 2013, 21, 1018-1029
3.929Citations (PDF)
219Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
New England Journal of Medicine, 2013, 369, 2083-2092
44.0566Citations (PDF)
220Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04
Journal of Virology, 2013, 87, 2294-2306
3.734Citations (PDF)
221<scp>HIV</scp>‐1 neutralizing antibodies: understanding nature's pathways
Immunological Reviews, 2013, 254, 225-244
6.6476Citations (PDF)
222Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Nature, 2013, 496, 469-476
39.51,043Citations (PDF)
223Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
Immunity, 2013, 38, 176-186
23.3392Citations (PDF)
224Mining the antibodyome for HIV-1–neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains
Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6470-6475
7.8149Citations (PDF)
225Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16
Nature Structural and Molecular Biology, 2013, 20, 804-813
8.7272Citations (PDF)
226De novo identification of VRC01 class HIV-1–neutralizing antibodies by next-generation sequencing of B-cell transcripts
Proceedings of the National Academy of Sciences of the United States of America, 2013, 110,
7.8108Citations (PDF)
227Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains
Journal of Virology, 2013, 87, 10047-10058
3.768Citations (PDF)
228Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates
Journal of Virology, 2013, 87, 13239-13251
3.765Citations (PDF)
229Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
PLoS ONE, 2013, 8, e53629
2.4175Citations (PDF)
230N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementation of Function
PLoS ONE, 2013, 8, e55701
2.438Citations (PDF)
231DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
PLoS ONE, 2013, 8, e59340
2.480Citations (PDF)
232Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
PLoS ONE, 2013, 8, e75665
2.4227Citations (PDF)
233Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
Nature, 2013, 505, 502-508
39.5147Citations (PDF)
234PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4
Journal of Virology, 2012, 86, 4394-4403
3.7115Citations (PDF)
235BLyS-Mediated Modulation of Naive B Cell Subsets Impacts HIV Env-Induced Antibody Responses
Journal of Immunology, 2012, 188, 6018-6026
0.634Citations (PDF)
236Most rhesus macaques infected with the CCR5-tropic SHIV <sub>AD8</sub> generate cross-reactive antibodies that neutralize multiple HIV-1 strains
Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19769-19774
7.875Citations (PDF)
237HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes
Journal of Virology, 2012, 86, 3393-3397
3.777Citations (PDF)
238Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site
Journal of Biological Chemistry, 2012, 287, 5673-5686
2.350Citations (PDF)
239The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
AIDS Research and Human Retroviruses, 2012, 28, 1444-1457
1.5202Citations (PDF)
240Anti-HIV B Cell Lines as Candidate Vaccine Biosensors
Journal of Immunology, 2012, 189, 4816-4824
0.660Citations (PDF)
241Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Immunity, 2012, 37, 412-425
23.3446Citations (PDF)
242Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates
Journal of Virology, 2012, 86, 7760-7770
3.735Citations (PDF)
243HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins
Journal of Virology, 2012, 86, 11231-11241
3.762Citations (PDF)
244Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site
Journal of Virology, 2012, 86, 5844-5856
3.782Citations (PDF)
245Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV <sub>AD8</sub> in Rhesus Macaques: Implications for Use in Vaccine Studies
Journal of Virology, 2012, 86, 8516-8526
3.749Citations (PDF)
246Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4<sup>+</sup>T Cells Is Directly Associated with the Magnitude of Surface IgG Binding
Journal of Virology, 2012, 86, 8672-8680
3.7101Citations (PDF)
247Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Nature, 2012, 491, 406-412
39.5824Citations (PDF)
248The Development of CD4 Binding Site Antibodies during HIV-1 Infection
Journal of Virology, 2012, 86, 7588-7595
3.7137Citations (PDF)
249Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design
Journal of Virology, 2012, 86, 4688-4692
3.7169Citations (PDF)
250Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops
Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5663-5668
7.8234Citations (PDF)
251High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site
Science Translational Medicine, 2012, 4,
13.4114Citations (PDF)
252Somatic populations of PGT135–137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatic
Frontiers in Microbiology, 2012, 3,
3.971Citations (PDF)
253Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors
Journal of Medicinal Chemistry, 2012, 55, 4382-4396
6.792Citations (PDF)
254A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
Journal of Infectious Diseases, 2011, 203, 1396-1404
3.9156Citations (PDF)
255Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01
Journal of Virology, 2011, 85, 8954-8967
3.7228Citations (PDF)
256Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors
Journal of Virology, 2011, 85, 9998-10009
3.7413Citations (PDF)
257Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals
Journal of Virology, 2011, 85, 11502-11519
3.7175Citations (PDF)
258Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
Science, 2011, 333, 1593-1602
37.0823Citations (PDF)
259DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Lancet Infectious Diseases, The, 2011, 11, 916-924
15.7187Citations (PDF)
260Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1
Journal of Virology, 2011, 85, 2524-2535
3.749Citations (PDF)
261HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies
AIDS Research and Human Retroviruses, 2011, 27, 877-887
1.562Citations (PDF)
262Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies
Journal of Virology, 2011, 85, 11401-11408
3.782Citations (PDF)
263Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys
Journal of Virology, 2011, 85, 6906-6912
3.768Citations (PDF)
264Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1
Cold Spring Harbor Perspectives in Medicine, 2011, 1, a007278-a007278
6.7139Citations (PDF)
265The <i>TRIM5</i> Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys
Journal of Virology, 2011, 85, 10389-10398
3.744Citations (PDF)
266Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses
Journal of Virology, 2011, 85, 5465-5475
3.747Citations (PDF)
267Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Nature, 2011, 480, 336-343
39.5837Citations (PDF)
268Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys
Science Translational Medicine, 2011, 3,
13.4178Citations (PDF)
269Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
PLoS ONE, 2010, 5, e9015
2.4126Citations (PDF)
270Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
Journal of Experimental Medicine, 2010, 207, 2003-2017
8.0107Citations (PDF)
271Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables
Journal of Virology, 2010, 84, 1631-1636
3.7318Citations (PDF)
272Influence of Novel CD4 Binding-Defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T-Cell Responses in Nonhuman Primates
Journal of Virology, 2010, 84, 1683-1695
3.744Citations (PDF)
273Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region
Journal of Virology, 2010, 84, 2955-2962
3.7109Citations (PDF)
274The Role of Antibodies in HIV Vaccines
Annual Review of Immunology, 2010, 28, 413-444
30.4365Citations (PDF)
275Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Science, 2010, 329, 811-817
37.01,130Citations (PDF)
276Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Science, 2010, 329, 856-861
37.01,718Citations (PDF)
277Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies
Journal of Virology, 2010, 84, 1439-1452
3.7632Citations (PDF)
278Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein
Journal of Virology, 2009, 83, 540-551
3.754Citations (PDF)
279Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment
Journal of Virology, 2009, 83, 10892-10907
3.787Citations (PDF)
280Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site
PLoS Pathogens, 2009, 5, e1000445
4.5114Citations (PDF)
281Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain
Journal of Virology, 2009, 83, 5077-5086
3.745Citations (PDF)
282Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
Journal of Experimental Medicine, 2009, 206, 1117-1134
8.0299Citations (PDF)
283A method for identification of HIV gp140 binding memory B cells in human blood
Journal of Immunological Methods, 2009, 343, 65-67
1.5217Citations (PDF)
284Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Nature Medicine, 2009, 15, 866-870
40.4394Citations (PDF)
285Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120
Science, 2009, 326, 1123-1127
37.0276Citations (PDF)
286Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
Current Opinion in HIV and AIDS, 2009, 4, 347-351
3.349Citations (PDF)
287A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
Vaccine, 2008, 26, 6338-6343
3.2242Citations (PDF)
288B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4
PLoS Pathogens, 2008, 4, e1000171
4.558Citations (PDF)
289A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial
Journal of Infectious Diseases, 2007, 196, 1732-1740
3.9183Citations (PDF)
290Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity
Journal of Virology, 2007, 81, 5579-5593
3.7101Citations (PDF)
291Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection
Journal of Virology, 2007, 81, 13486-13498
3.750Citations (PDF)
292Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
Vaccine, 2007, 25, 4085-4092
3.2137Citations (PDF)
293Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions
PLoS Medicine, 2007, 4, e348
8.180Citations (PDF)
294Broad HIV-1 neutralization mediated by CD4-binding site antibodies
Nature Medicine, 2007, 13, 1032-1034
40.4369Citations (PDF)
295Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
Virology, 2006, 350, 34-47
2.3102Citations (PDF)
296Gene transfer in humans using a conditionally replicating lentiviral vector
Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17372-17377
7.8470Citations (PDF)
297Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys
Science, 2006, 312, 1530-1533
37.0348Citations (PDF)
298Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge
Journal of Virology, 2006, 80, 10950-10956
3.754Citations (PDF)
299Preservation of Functional Virus-Specific Memory CD8+ T Lymphocytes in Vaccinated, Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys
Journal of Immunology, 2006, 176, 5338-5345
0.634Citations (PDF)
300Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys
Journal of Virology, 2005, 79, 2956-2963
3.7120Citations (PDF)
301A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates
Journal of Virology, 2005, 79, 8828-8834
3.7171Citations (PDF)
302Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus-Induced IL-2 Expression by Central Memory CD4+ T Lymphocytes
Journal of Immunology, 2005, 174, 4753-4760
0.628Citations (PDF)
303Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys
Journal of Virology, 2005, 79, 4580-4588
3.727Citations (PDF)
304Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells
Journal of Experimental Medicine, 2005, 201, 2023-2033
8.0186Citations (PDF)
305Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins
Journal of Virology, 2005, 79, 771-779
3.7101Citations (PDF)
306Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates
Journal of Virology, 2005, 79, 6516-6522
3.7142Citations (PDF)
307Differential Susceptibility to Human Immunodeficiency Virus Type 1 Infection of Myeloid and Plasmacytoid Dendritic Cells
Journal of Virology, 2005, 79, 8861-8869
3.7198Citations (PDF)
308Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus
Journal of Virology, 2005, 79, 10902-10914
3.735Citations (PDF)
309Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Journal of Virology, 2005, 79, 10108-10125
3.71,076Citations (PDF)
310Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination
Journal of Virology, 2004, 78, 5520-5522
3.723Citations (PDF)
311Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins
Journal of Virology, 2004, 78, 5270-5278
3.740Citations (PDF)
312Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope
Journal of Virology, 2004, 78, 10724-10737
3.7472Citations (PDF)
313Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys
Journal of Virology, 2004, 78, 7490-7497
3.7127Citations (PDF)
314Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope
Journal of Virology, 2004, 78, 4029-4036
3.769Citations (PDF)
315Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1
AIDS Research and Human Retroviruses, 2003, 19, 807-816
1.527Citations (PDF)
316Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies
Journal of Virology, 2003, 77, 10348-10356
3.750Citations (PDF)
317Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort
Aids, 2003, 17, 2521-2527
2.564Citations (PDF)
318Defining the Protective Antibody Response for HIV-1
Current Molecular Medicine, 2003, 3, 209-216
2.2122Citations (PDF)
319Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells
Journal of Virology, 2002, 76, 4810-4821
3.7108Citations (PDF)
320Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination
Journal of Virology, 2002, 76, 11484-11490
3.747Citations (PDF)
321Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection
AIDS Research and Human Retroviruses, 2001, 17, 1021-1034
1.527Citations (PDF)
322Vaccines for the prevention of HIV-1 disease
Current Opinion in Immunology, 2001, 13, 489-494
5.362Citations (PDF)
323Human Dendritic Cells as Targets of Dengue Virus Infection
Journal of Investigative Dermatology Symposium Proceedings, 2001, 6, 219-224
2.1155Citations (PDF)
324Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel
Aids, 2000, 14, 1009-1015
2.5103Citations (PDF)
325Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
Nature Medicine, 2000, 6, 207-210
40.41,258Citations (PDF)
326Human skin Langerhans cells are targets of dengue virus infection
Nature Medicine, 2000, 6, 816-820
40.4626Citations (PDF)
327Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion
Journal of Virology, 2000, 74, 11329-11338
3.7109Citations (PDF)
328Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes
Journal of Clinical Microbiology, 1999, 37, 2557-2563
4.1124Citations (PDF)
329Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies
Journal of Virology, 1999, 73, 4009-4018
3.7743Citations (PDF)
330A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-Reacts with Other HIV Type 1 Clades
AIDS Research and Human Retroviruses, 1998, 14, 213-221
1.524Citations (PDF)
331The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
Nature Medicine, 1997, 3, 338-340
40.4483Citations (PDF)
332Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay
AIDS Research and Human Retroviruses, 1996, 12, 1319-1328
1.579Citations (PDF)
333Induction of HIV Type 1 Neutralizing and<i>env</i>-CD4 Blocking Antibodies by Immunization with Genetically Engineered HIV Type 1-Like Particles Containing Unprocessed gp160 Glycoproteins
AIDS Research and Human Retroviruses, 1995, 11, 1187-1195
1.521Citations (PDF)
334Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization Serotype
Journal of Infectious Diseases, 1994, 169, 48-54
3.9195Citations (PDF)
335Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine Trials
AIDS Research and Human Retroviruses, 1993, 9, 1175-1184
1.599Citations (PDF)